YAKUGAKU ZASSHI
Online ISSN : 1347-5231
Print ISSN : 0031-6903
ISSN-L : 0031-6903
Regular Articles
Evaluation of Drug-drug Interaction Potential of Beraprost Sodium Mediated by P450 In Vitro
Tominaga FUKAZAWAKanako YAJIMAYohei MIYAMOTO
Author information
JOURNAL FREE ACCESS

2008 Volume 128 Issue 10 Pages 1459-1465

Details
Abstract

  Beraprost sodium (BPS), a chemically stable and orally active prostacyclin analogue used for the treatment of chronic occlusive disease and primary pulmonary hypertension, was investigated in terms of its drug-drug interaction mediated by cytochrome P450. In a metabolic enzyme characterization study using P450-expressing insect cell microsomes, beraprost (BP) was slightly metabolized in the presence of CYP2C8, but not metabolized by the other P450 isoforms (CYP1A1, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP4A11) at a concentration of 20 μM. These results suggest that none of the P450 isoforms is a major metabolic enzyme of BP. In a P450 induction study using human hepatocytes, BP did not induce any P450 isoform (CYP1A2, CYP2C9, CYP2C19, and CYP3A4) at concentrations of 1-100 μM. Furthermore, in a P450 inhibition study using human liver microsomes, BP did not inhibit any P450 isoform (CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) at concentrations of 0.05-1 μM. Therefore it is concluded that BP is not involved in drug-drug interaction mediated by P450 isoforms.

Content from these authors
© 2008 by the PHARMACEUTICAL SOCIETY OF JAPAN
Previous article Next article
feedback
Top